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ABSTRACT
Myeloperoxidase is expressed exclusively in granulocytes and
immature myeloid cells and transforms the topoisomerase II
(TOP2) poisons etoposide and mitoxantrone to chemical forms
that have altered DNA damaging properties. TOP2 poisons are
valuable andwidely used anticancer drugs, but they are associated
with the occurrence of secondary acute myeloid leukemias. These
factors have led to the hypothesis that myeloperoxidase inhibition
could protect hematopoietic cells from TOP2 poison-mediated
genotoxic damage and, therefore, reduce the rate of therapy-
related leukemia.We showhere thatmyeloperoxidase activity leads
to elevated accumulation of etoposide- and mitoxantrone-induced
TOP2A and TOP2B-DNA covalent complexes in cells, which are
converted to DNA double-strand breaks. For both drugs, the effect
ofmyeloperoxidase activity was greater for TOP2B than for TOP2A.
This is a significant finding because TOP2B has been linked to
genetic damage associatedwith leukemic transformation, including
etoposide-induced chromosomal breaks at the MLL and RUNX1
loci. Glutathione depletion, mimicking in vivo conditions experi-
enced during chemotherapy treatment, elicited further MPO-
dependent increase in TOP2A and especially TOP2B-DNA
complexes and DNA double-strand break formation. Together
these results support targeting myeloperoxidase activity to reduce
genetic damage leading to therapy-related leukemia, a possibility
that is enhanced by the recent development of novel specific
myeloperoxidase inhibitors for use in inflammatory diseases in-
volving neutrophil infiltration.
Introduction
Drugs targeting DNA topoisomerase II (TOP2 poisons) are
important, effective, and widely used anticancer agents, but
they are associated with short- and long-term toxic side
effects, including neutropenia and rare but life-threatening
therapy-related acute myeloid leukemia (t-AML) (Allan and
Travis, 2005; Leone et al., 2010; Cowell and Austin, 2012). As
cancer survival rates have increased, t-AML has become a
more important clinical problem, and it is estimated that up
to 15% of all acute myeloid leukemia cases can be classified
as t-AML (Mauritzson et al., 2002). Therapy-related acute
leukemias occur after a wide range of primary neoplasias, but
prior treatment of breast cancer accounts for about 50% of
cases, while hematological malignancies account for approx-
imately 30% (Kayser et al., 2011). In its normal cellular role,
TOP2 facilitates changes to DNA topology by allowing one
double stranded segment to pass through another via an
enzyme-bridged DNA double-strand break (DSB) (Austin and
Marsh, 1998; Vos et al., 2011; Cowell andAustin, 2012). In this
configuration, each protomer of the homodimeric TOP2 en-
zyme is covalently coupled to a cleaved DNA strand via a 59-
phosphotyrosine linkage. TOP2 poisons such as etoposide and
mitoxantrone exert their tumoricidal effect by stabilizing this
normally transient enzyme-bridged break, resulting in the
accumulation of cytotoxic covalently linked TOP2 protein-
DNA complexes, which can be processed in the cell to DNA
double-strand breaks (Burma et al., 2001; Cowell and Austin,
2012; Lee et al., 2012, 2016). Therapy related leukemias,
especially those appearing after exposure to TOP2 poisons
often contain recurrent chromosome translocations, includ-
ing t(15,17)(PML-RARA), t(8,21)(AML-ETO), and 11q23 re-
arrangements involving the MLL gene (Rowley and Olney,
2002; Cowell and Austin, 2012). These genetic lesions disrupt
blood cell development and play a pivotal role in the develop-
ment of the disease. Such t-AML cases arise as a result of
TOP2 poison-mediated DNA damage in bone marrow blood
precursor cells. There are two vertebrate TOP2 paralogues,
TOP2A and TOP2B; TOP2 poisons such as etoposide affect
both paralogues, but recent evidence points to a greater role
for TOP2B in generating the genotoxic damage associated
with TOP2 poisons (Azarova et al., 2007; Cowell et al., 2012;
Smith et al., 2014a).
This work was supported by Breast Cancer Now [Grant 2012Novem-
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break; GSH, reduced glutathione; H2AX, histone H2A.X; gH2AX, S-139 phospho histone H2A.X; MPO, myeloperoxidase; MPOi-II, 4-(5-fluoro-1H-
indol-3-yl)butanamide; PF-1355, 2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide; SA, succinylacetone; TAR-
DIS, trapped in agarose DNA immunostaining assay; t-AML, therapy-related acute myeloid leukemia; TOP2, topoisomerase II; TOP2A, DNA
topoisomerase IIb; TOP2B, DNA topoisomerase IIb; TOP2-CC, topoisomerase II covalent complex.
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We are interested in why cells of the myeloid hematopoietic
lineage are sensitive to TOP2 poison-mediated genotoxic
damage, which leads to t-AML, and how this sensitivity could
be reduced. Myeloperoxidase is expressed exclusively in
cells of the myeloid lineage; it is present at high levels in
neutrophils where it exerts its antimicrobial action but is also
expressed in myeloid precursor/progenitor cells, including
human and mouse common myeloid progenitor and granulo-
cyte/macrophage progenitor cells (Strobl et al., 1993; Mori
et al., 2009; Goardon et al., 2011) and is readily detectable in
ex vivo normal human bone marrow CD341 cells (Supple-
mental Fig. 1) (Strobl et al., 1993; Vlasova et al., 2011). Thus,
MPO is likely to be present in the cells in which t-AML arises.
In its physiologic role MPO generates hypochlorous acid from
hydrogen peroxide and chloride ions to kill pathogenic micro-
organisms. However, MPO activity also leads to the oxidative
activation of etoposide. This occurs by one-electron oxidation
of the etoposide E-ring, yielding a phenoxy radical species and
byO-demethylation to the reactive orthoquinone (Supplemen-
tal Fig. 2A) (Haim et al., 1986; Kalyanaraman et al., 1989;
Kagan et al., 2001; Fan et al., 2006; Jacob et al., 2011; Vlasova
et al., 2011). Additionally, CYP3A4 and/or CYP3A5 can oxidize
etoposide to etoposide catechol, a metabolite found in patient
plasma (Zheng et al., 2004; Zhuo et al., 2004), and oxidation of
etoposide by CYP3A4 has been implicated in the incidence of
t-AMLs (Felix et al., 1998). Etoposide catechol can be oxidized to
etoposide quinone by MPO via a semiquinone species (Supple-
mental Fig. 2A). Etoposide quinone is more effective at inducing
TOP2-mediatedDNAbreaks than etoposide in vitro (Jacob et al.,
2011) and this is particularly true for TOP2B (Smith et al.,
2014b). This increased potency of etoposide quinone as a TOP2
poison has been attributed to covalent modification of the en-
zyme by the quinone (Jacob et al., 2011; Smith et al., 2014b).
Furthermore, etoposide metabolites have the potential to form
adducts with DNA and protein (Haim et al., 1987; Lovett et al.,
2001), which may also impact on genotoxicity.
Oxidative activation of TOP2 poisons is not limited to
etoposide because MPO has been implicated in the activation
of mitoxantrone either directly or via the production of
reactive aldehydes (Panousis et al., 1995, 1997; Hazen et al.,
1998; Parker et al., 1999; Evison et al., 2016).
Using pharmacological inhibition and genetic manipula-
tion we show that MPO activity increases etoposide and
mitoxantrone-induced formation of TOP2A and TOP2B cova-
lent enzyme-DNA complexes in cells of myeloid origin and
similarly increases DSB formation. GSH depletion amplified
this effect. This is consistent with the hypothesis that MPO
inhibition, in a clinical setting, especially where cellular thiol
levels are suppressed, could protect against genotoxic damage
in the myeloid compartment by TOP2 poisons.
Materials and Methods
Reagents and Antibodies. Etoposide, mitoxantrone, succinylacetone
(SA), dimethyl sulfoxide, Tween 20, Triton X-100, paraformaldehyde,
DL-buthionine sulfoximine and PF-1355 (2-(6-(2,5-dimethoxyphenyl)-4-
oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide) were purchased
from Sigma-Aldrich (Dorset, UK). MPOi-II (4-(5-fluoro-1H-indol-3-yl)
butanamide) was purchased fromMerck-Millipore (Watford, UK). Anti-
MPO ab9535 (immunofluorescence) and ab134132 (Western blotting) were
from Abcam (Cambridge UK), anti-mouse gH2AX 05-636 was obtained
from Merck-Millipore.
Cell Culture. All cell lines were maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum and 1% penicillin
and streptomycin (Thermo Fisher Scientific, Paisley, UK). Cells were
cultured at 37°C in a humidified atmosphere containing 5% CO2.
Experiments were conducted on cells growing in log phase (2–5 
105cells/ml). For succinylacetone treatment of cells to downregulate
MPO, cells were treated with 200 mM SA for 48 hours before addition
of TOP2 poison and downstream analysis. SA was retained during
TOP2 poison treatment.
Stable Transfection of K562 Cells with MPO cDNA. K562
cells were transfected with plasmid RC2016029 containing the MPO
coding sequence with a C-terminal MYC-DDK tag in the vector pCMV
6-Entry (Origene, Rockville, MD). Transfection was performed using
Dharmafect Duo (Dharmacon, Amersham, UK) transfection reagent.
Transfectionmixtures contained 1 mg/ml of MPO plasmid (Origene) or
G418 control plasmid with 20 mg/ml of Dharmafect Duo (Dharmacon)
and 80% v/v serum-free RPMI 1640 medium. After selection with
G418 (750 mg/ml), clonal lines were isolated by limited dilution. MPO-
expressing lines were continuously grown in 500 mg/ml G418, the
selection antibiotic. MPO expression was assessed using immunoflu-
orescence and MPO activity assays.
MPO and GSH Colorimetric Activity Assays. MPO activity
assays were performed using an Abcam MPO Activity Assay kit
(ab105136, Abcam). Cells were harvested by centrifugation at 1000 g
for 5 minutes and homogenized in 4 pellet volumes of lysis buffer
provided. Bradford assays were conducted to ensure an equal
concentration of protein was used for each assay. The MPO activity
assay was conducted according to manufacturer’s instructions with
absorbance readings measured at 415 nm. GSH assays were per-
formed using a GSH assay kit (KA0797, Abnova, Taipei City, Taiwan),
according to the manufacturer’s instructions.
Immunoblotting for MPO. Whole cell lysates of cells were
prepared (Mirski et al., 1993) and samples were resolved on precast
4–20% SDS-polyacrylamide gels (NuSep, Wasserburg, Germany).
Western blotting was performed by standard methods using ECL
detection.
Trapped in Agarose DNA Immunostaining Assay. Trapped in
agarose DNA immunostaining (TARDIS) assays to quantify TOP2
covalent protein-DNA complexes were carried out essentially as
described previously (Willmore et al., 1998; Cowell et al., 2011b).
Briefly cells were treated for 1 hour with the desired dose of etoposide
or mitoxantrone. Cells were then pelleted and washed in ice-cold PBS.
After being recentrifuged, cells were mixed with molten 2% LMP
agarose (Lonza, Basel, Switzerland) in PBS at 37°C and spread evenly
onto agarose coated slides. Agarose-embedded cells were lysed in (1%
w/v SDS, 20 mM sodium phosphate, 10 mM EDTA, pH 6.5) and
noncovalently DNA bound proteins were removed using 1 M NaCl.
TOP2 covalent complexeswere detected by immunofluorescence using
rabbit anti-TOP2A (4566) or anti-TOP2B (4555) antibodies, raised to
the C-terminal domain of human TOP2A and TOP2B, respectively,
and Alexa-488 coupled anti-rabbit secondary antibodies (Thermo
Fisher Scientific). Slides were counterstained with Hoechst 33258 to
visualize DNA. Quantitative immunofluorescence was performed by
capturing images for Hoechst and Alexa-488 using a epifluorescence
microscope (Olympus IX-81, Olympus, Tokyo, Japan) fitted with an
Orca-AG camera (Hamamatsu, Tokyo, Japan) and suitable narrow
band filter sets. Images were analyzed using Volocity 6.3 (Perkin
Elmer, Waltham, MA), and data representation and statistics were
performed using GraphPad Prism 4.0 and R (San Diego, CA).
Immunofluorescence Analysis of gH2AX and MPO. After
drug treatment cells were washed and pelleted in ice-cold PBS and
spotted onto poly-L-lysine slides. Cells were fixed in 4% formaldehyde
in PBS and permeabilized using KCM1T buffer (120 mMKCl, 20 mM
NaCl, 10 mMTris-HCl pH 8.0, 1 mMEDTA, 0.1% Triton X-100). After
blocking in (KCM1T, 2% bovine serum albumin, 10% dry milk
powder) cells were probed with primary anti-MPO antibody or anti-
gH2AX in blocking buffer and Alexa-488 anti-rabbit or Alexa-594 anti-
mouse secondary antibodies (Thermo Fisher Scientific). Slides were
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counterstained with DAPI (4’,6-diamidino-2-phenylindole) (Vector
Laboratories, Burlingame, CA) and viewed using an epifluorescence
microscope (Olympus IX-81). For gH2AX quantification, images were
captured for DAPI and Alexa-594 and quantitative analysis was
performed using Volocity 6.3 (Perkin Elmer) with data representation
performed in GraphPad Prism 4.0 and R.
GSH Depletion. NB4 cells were treated with 150 mM buthionine
sulfoximine (BSO) for 4.5 hours (Griffith, 1982; Gantchev and Hunting,
1997) before addition of TOP2 poison. BSO was retained in the medium
during TOP2 poison treatment.
Statistics. Data are presented as themean values6 S.E.M. values
for n $ 3 replicate experiments; the number of replicates involved for
each treatment is indicated within the figures. Statistical analysis
was performed by one-way ANOVA with post hoc Tukey’s multi-
ple comparison test. For signifying P values, * refers to P , 0.05,
** refers to P , 0.01, and *** refers to P , 0.001.
Results
MPO Inhibition Suppresses Etoposide-Induced
TOP2A and TOP2B Covalent DNA Complex Formation
in NB4 Cells. MPO activity can be efficiently reduced in cell
culture systems by the heme biosynthesis inhibitor succiny-
lacetone (SA) (Pinnix et al., 1994; Kagan et al., 2001; Vlasova
et al., 2011). By using NB4 cells, an acute promyleocytic
leukemia line that express MPO at a high level (Hu et al.,
1993), we found that incubation with 200 mM SA for 48 hours
reducedMPO enzymatic activity to below the detection level of
the assay employed, and as reported previously (Pinnix et al.,
1994), it significantly depleted mature MPO protein (Fig. 1, A
and B). Quantification of replicate blots indicated that mature
MPO protein level was reduced to less than 25% of that in
untreated cells. Notably, SA treatment of up to 72 hours did
not affect TOP2A or TOP2B protein levels in NB4 cells,
accelerate acidification of the medium, nor reduce cell via-
bility or cell growth (Supplemental Fig. 2, B–E). Similarly,
SA did not affect TOP2A or TOP2B enzymatic activity in
vitro (Supplemental Fig. 2, F–H). We used the TARDIS
assay (Willmore et al., 1998; Cowell et al., 2011b) to quan-
tify stabilized TOP2-DNA covalent complexes in etoposide-
treated cells. This assay employs sensitive quantitative
immunofluorescence to analyze TOP2 content in agarose
embedded “nuclear ghosts” that remain after noncovalently
attached proteins and other cellular constituents have been
removed from nuclear DNA by SDS-salt extraction (Supple-
mental Fig. 3, A and B). Pretreatment with SA significantly
reduced the levels of etoposide-induced TOP2A and TOP2B-
DNA complexes. This was true for both 10 and 100 mM
etoposide (Fig. 1, C and D; Supplemental Fig. 3, A and B). At
both doses of etoposide, the magnitude of the affect was
greater for TOP2B than for TOP2A. For TOP2B with
100 mM etoposide SA pretreatment resulted in a 38% re-
duction in TOP2-complex formation, whereas the reduction
was 12% for TOP2A. For 10 mM etoposide, the respective
figures were 55% and 18% (Fig. 1, C and D; Supplemental
Table 1). As expected, SA pretreatment did not affect stabi-
lized TOP2A or TOP2B-DNA complexes in K562 cells, a
chronic myeloid leukemia-derived cell line that does not
express MPO (Supplemental Fig. 3, C and D). Etoposide
quinone displays enhanced TOP2-mediated DNA cleavage
activity in vitro compared with the parent compound (Jacob
et al., 2011), and this is more pronounced for TOP2B (Smith
et al., 2014b). The observation that SA pretreatment, which
reducesMPO-mediated etoposide phenoxy radical production,
partially suppressed etoposide-induced TOP2-CC formation
in MPO-expressing NB4 cells supports the conclusion that
oxidative metabolism of etoposide plays a role in TOP2-
mediated DNA damage in vivo.
MPO Expression in K562 Cells Stimulates Etoposide-
Induced TOP2-DNA Covalent Complex Formation.
K562 is a chronic myeloid leukemia derived cell line that
does not express detectable MPO (Hu et al., 1993) (Supple-
mental Fig. 1). We transfected K562 cells with a human MPO
expression construct and isolated clonal K562 lines expressing
MPO. Two K562MPO cell lines (MPO line 4 and MPO line 5)
exhibited MPO activity at 37 6 7.5% and 46 6 6.0% of the
level of NB4 cells, respectively. Both cell lines expressed MPO
in all cells by immunofluorescence (Fig. 2A). Parental K562
cells and K562MPO cell lines 4 and 5 were treated with 10 or
100 mM etoposide and stabilized TOP2-DNA complexes were
quantified. The K562MPO cell lines displayed significantly
higher levels of drug-stabilized complexes for both TOP2
isoforms compared with K562 cells lacking MPO expression
at 100 mM etoposide. At 10 mM etoposide, raised levels of
TOP2A and TOP2B stabilized complexes were observed with
MPO line 5, and for line 4 significantly raised complex levels
Fig. 1. MPO inhibition reduces the level of TOP2-DNA covalent com-
plexes formed by etoposide in NB4 cells. (A and B) Succinylacetone (SA)
abolishedMPO activity (A) and reduced mature protein levels in NB4 cells
(B); NB4 cells were treated with 200 mM SA for 48 hours and assayed for
MPO activity (A) and MPO protein level by Western blotting of whole cell
extracts (B). Blots were quantified by densitometry. (C and D) TOP2-DNA
covalent complexes were quantified by TARDIS analysis using antibodies
specific to TOP2A (C) or TOP2B (D). Integrated fluorescence values were
determined per nucleus (at least 500 nuclei per treatment per replicate
experiment). From these, median values were obtained for each treatment
and means of the medians were calculated from replicate experiments (n =
3). Data are expressed as a percentage of the mean value obtained with
100 mM etoposide in the absence of SA, 6S.E.M. Integrated fluorescence
data corresponding to an individual experiment are also shown in
Supplemental Fig. 3, A and B. *P , 0.05.
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were observed only for TOP2A (Fig. 2B). After subtracting
background complex levels, K562MPO line 5 displayed a 1.6-
and 2.0-fold increase in TOP2A- and TOP2B-DNA complexes,
respectively, compared with K562 after 100 mM etoposide
treatment. For line 4, which expressedMPO at a lower level, a
smaller fold increase in complexes was observed (Supplemen-
tal Table 1). By comparison, K562 cells transfected with an
empty expression vector did not display increased TOP2
covalent complex formation (Supplemental Fig. 3, G and H).
This further supports the notion that MPO-mediated activa-
tion contributes to etoposide-mediated DNA damage in MPO
expressing cells.
MPO Contributes to Etoposide-Induced Cellular
DNA Damage. TOP2 poison-induced covalent DNA complexes
are processed to DSBs that result in histone H2AX phosphory-
lation (Sunter et al., 2010; Cowell et al., 2011a, 2012) as part of
a well-established response involving activation of the DNA
damage kinase ataxia-telangiectasia mutated (Burma et al.,
2001). Thus,gH2AXcanbeusedas ameasure ofDSBsgenerated
by etoposide treatment. The inhibition ofMPOusing SA resulted
in a 40% reduction in gH2AX induced by 100 mM etoposide (Fig.
3A; Supplemental Table 1). Notably, this is equivalent to the
difference in gH2AX signal observed between 10 and 100 mM
etoposide in the absence of SA. SA did not significantly affect the
level of gH2AX observed after exposure to 10 mM etoposide. SA
had no effect on etoposide-induced gH2AX in K562 cells, which
do not express MPO (Supplemental Fig. 3E).
Etoposide-induced gH2AX formation was also examined in
K562MPO cell lines. For 10 mM etoposide, MPO expression
resulted in a significant rise in gH2AX intensity (Fig. 3B),
reaching a 1.8-fold increase over K562 cells for line 5 (Supple-
mental Table 1). At 100 mM etoposide, neither cell line
displayed a significant increase in gH2AX over K562. How-
ever, the lack of significant effect of MPO expression when
cells were treated with 100 mM compared with the lower
etoposide dose can be explained by the observation that
gH2AX formation reaches saturation at 100 mM etoposide in
K562 cells (Supplemental Fig. 3F).
K562 cells transfected with empty vector were also tested
for induction of gH2AX formation in comparison with non-
transfected K562 cells. The empty vector control did not differ
significantly from the nontransfected cells in gH2AX signal
formation upon etoposide treatment (Supplemental Fig. 3I).
Thus, MPO activity results in elevatedH2AX phosphorylation
in etoposide-treated cells.
MPO Stimulates Mitoxantrone-Induced Accumulation
of TOP2-DNA Complexes and H2AX Phosphorylation.
The inhibitor SA, which effectively abolishes MPO activity
in NB4 cells (Fig. 1), resulted in a substantial reduction in
stabilized TOP2-DNA complexes induced by mitoxantrone
(Fig. 4A). After subtraction of signal detected in control cells
(0 mM mitoxantrone), TOP2A and TOP2B complexes in-
duced by 0.5 mMmitoxantrone were reduced by 59 and 88%,
respectively, whereas at 1 mMmitoxantrone the figures were
Fig. 3. MPOactivity results in raised levels of etoposide-
induced H2AX phosphorylation. (A) NB4 cells were
pretreated for 48 hours with SA (200 mM) then
incubated with etoposide (10 or 100 mM). (B) K562
and K562MPO cell lines were incubated with 10 and
100 mM etoposide or dimethyl sulfoxide vehicle
control. For both (A) and (B), gH2AX was quantified
by immunofluorescence. Analysis was carried out as
described for TARDIS analysis in Fig. 1. Data are
expressed relative to the mean values obtained with
100 mM etoposide in the absence of SA (A) or in wild-
type parental K562 cells (B). Numbers of replicates
are indicated. *P , 0.05; **P , 0.01; ***P , 0.001.
Fig. 2. Expression of active MPO in K562 cells increases the level of
etoposide-stabilized TOP2-DNA covalent complexes. (A) Comparison of
MPOactivity (left) andMPO immunofluorescence (right) in K562 cells, two
MPO-expressing K562-derived cell lines (K562MPO line4 K562MPO line5), and
in NB4 cells. (B) K562 and K562MPO cell lines were incubated with 10 or
100 mM Etoposide or a vehicle control for 1 hour. Etoposide-stabilized
TOP2-DNA complexes were quantified by TARDIS analysis using anti-
bodies specific for TOP2A or TOP2B as described for Fig. 1. Numbers of
replicates are indicated. *P , 0.05; **P , 0.01; ***P , 0.001.
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43% and 63% (Supplemental Table 1). Similarly, SA pre-
treatment reduced the mitoxantrone induced gH2AX signal
by 39% for 1 mM mitoxantrone (Fig. 4B).
K562MPO cell line 2 expresses MPO activity at 20% of the
level observed in NB4 cells (Fig. 4C). Mitoxantrone (1 mM)
induced 2.2- and 2.9-fold more stabilized TOP2A and TOP2B
complexes in K562MPO cell line 2 than in parental K562 cells
(Fig. 4D; Supplemental Table 1).
Like etoposide, mitoxantrone is prone to oxidation by
peroxidases such as MPO, and mitoxantrone can form DNA
adducts via activation by formaldehyde (Panousis et al., 1995;
Parker et al., 1999), but less is known about the impact of this
on TOP2-DNA complex formation in cells or the downstream
accumulation of DNA DSBs. The observed MPO activity
requirement for maximal TOP2 complex formation as well
as H2AX phosphorylation supports the idea that MPO-
mediated oxidation directly or indirectly enhances the activity
of mitoxantrone as a TOP2 poison.
Glutathione Depletion Stimulated Etoposide- and
Mitoxantrone-Induced DNA Damage in an MPO-Dependent
Manner. Etoposide and mitoxantrone metabolites react
with the low molecular weight thiol GSH (Yalowich et al.,
1996; Panousis et al., 1997; Kagan et al., 2001; Fan et al.,
2006). It follows that the effect of high MPO expression on
TOP2 poison-mediated DNA damage in cells may therefore
be limited by cellular GSH. To test this we used buthionine
sulfoximine (BSO), which inhibits g-glutamylcysteine syn-
thetase and thus leads to GSH depletion in cells (Griffith,
1982). The addition of BSO did not affect TOP2 activity
in in vitro activity assays (Supplemental Fig. 2, F–H).
Glutathione levels were reduced by more than 70% after
pretreatment with BSO (150 mM, 4.5 hours; Fig. 5A). BSO-
treated NB4 cells exhibited elevated levels of TOP2A- and
TOP2B-DNA complexes induced by 10 mM etoposide (1.9- and
3.4-fold, respectively), and for 100 mM etoposide BSO in-
creased TOP2B-DNA complexes (1.6 fold) but did not increase
TOP2A-DNA complex levels (Fig. 5, B and C; Supplemental
Table 2). In addition, BSO pretreatment significantly in-
creased etoposide-induced H2AX phosphorylation at both
doses of etoposide (2.2- and 2.0-fold increase, respectively;
Fig. 5D; Supplemental Table 2). Significantly, BSO had no
effect on TOP2 complexes or H2AX phosphorylation induced
by etoposide when cells were pretreated with the MPO
inhibitor SA. This is consistent with the previously described
Fig. 4. MPO activity enhances mitoxantrone-induced TOP2-DNA covalent complex formation and H2AX phosphorylation. (A and B) NB4 cells were
pretreated with 200 mM SA for 48 hours followed by a 1-hour incubation with 0.5 or 1 mM mitoxantrone, or a vehicle control. TOP2-DNA covalent
complexes and gH2AX were quantified as in Figs. 1 and 3. Data are expressed relative to the mean values obtained with 1 mM mitoxantrone in the
absence of SA. (C) Quantification of MPO activity in K562MPO line 2 compared with NB4 and parental K562 cells. (D) MPO expression in K562 cells
results in enhanced mitoxantrone-induced TOP2-DNA protein complex formation. Data are expressed relative to the mean value obtained for parental
K562 cells treated with 1 mM mitoxantrone. Numbers of replicates are indicated. *P , 0.05; **P , 0.01; ***P , 0.001.
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MPO-dependent (and therefore SA-suppressed) generation of
etoposide quinone via the phenoxy-radical (Haim et al., 1986;
Kagan et al., 2001), leading to elevated TOP2-DNA complex
accumulation and histone H2AX phosphorylation due to
elevated TOP2 poison activity (Gantchev and Hunting,
1998; Jacob et al., 2011). This activity is then enhanced
under conditions of depleted glutathione, which would
otherwise reduce the phenoxy radical and/or combine with
etoposide quinone. BSO pretreatment also resulted in elevated
mitoxantrone-induced stabilized TOP2-DNA complexes and
H2AX phosphorylation (Fig. 6, A–C), although the magnitude
of the effect was smaller than for etoposide (Fig. 5; Supplemen-
tal Table 3).
Direct Small Molecule Inhibitors of MPO Suppress
Etoposide- and Mitoxantrone-Induced TOP2A and
TOP2B Covalent DNA Complex Formation and H2AX
Phosphorylation in NB4 Cells. The work described above
employed the heme synthesis inhibitor SA that indirectly
reduces cellular MPO activity. Recently a number of direct
specific MPO inhibitors have been developed. These include
PF-1355 (2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-
dihydropyrimidin-1(2H)-yl)acetamide) (Zheng et al., 2015) and
MPOi-II (4-(5-fluoro-1H-indol-3-yl)butanamide) (Soubhye
et al., 2013). As expected, both of these inhibitors dramatically
reduced MPO activity in NB4 cells (Supplemental Fig. 4).
After 4 hours, MPO activity was undetectable in PF-1355-
treated cells and for MPOi-II activity was reduced by more
than 90%. Pretreatment with either inhibitor also reduced the
levels of TOP2A and TOP2B DNA complexes and H2AX
phosphorylation induced by etoposide or mitoxantrone in
NB4 cells, having a greater effect on TOP2B (Fig. 7). The
magnitudes of the effects were comparable to those observed
with SA pretreatment (Supplemental Table 2; Figs. 1, C and
D, 3A, and 4, A and B). As was observed for SA, PF-1355 and
MPOi-II did not affect induction of TOP2A or TOP2B com-
plexes or H2AX phosphorylation induced by etoposide or
mitoxantrone in MPO nonexpressing K562 cells (Supplemen-
tal Fig. 4).
Discussion
Therapy-related acute leukemia is a rare, but life threaten-
ing, complication of prior treatment of a primary cancer.
Therefore, interventions that specifically protect myeloid cells
from the unwanted effects of cytotoxic chemotherapies would
be very welcome. MPO is expressed exclusively in cells of
myeloid origin and is capable of enzymatic conversion of TOP2
poisons, including etoposide, mitoxantrone, and anthracy-
clines, to species with greater DNA damaging activity. So, in
principle, MPO inhibition should partially protect myeloid
precursors from TOP2 poison-mediated DNA damage, while
preserving the desired cytotoxic effects in the target tumor
cells. This idea is supported by the data reported here showing
that three chemically distinct MPO inhibitors each reduce
etoposide and mitoxantrone-induced TOP2-DNA complex
and gH2AX formation in NB4 cells, whereas conversely,
Fig. 5. Glutathione depletion increases etoposide-mediated TOP2-DNA covalent complex formation and H2AX phosphorylation. (A) BSO preincubation
(150 mM, 4.5 hours) resulted in 70% reduction of total and reduced glutathione in NB4 cells. (B–D) NB4 cells were incubated in the presence or absence of
SA (200 mM) for 48 hours, BSO (150 mM) for 4.5 hours, with both or with neither, followed by addition of 10 or 100 mM etoposide for 1 hour. TARDIS and
gH2AX assays were performed as described in Figs 1 and 3. Numbers of replicates are indicated. *P , 0.05; **P , 0.01; ***P , 0.001.
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exogenous MPO expression in K562 cells leads to increased
etoposide- and mitoxantrone-induced damage.
Notably, the suppression of MPO activity had an approxi-
mately threefold greater effect on TOP2B complex formation
than on TOP2A. The greater effect for TOP2B is of interest,
because this TOP2 isoform appears to be required for the
majority of etoposide-inducedMLL and RUNX1 chromosomal
breaks (Cowell et al., 2012; Smith et al., 2014a) in a human
lymphoblastoid cell line model and for etoposide-mediated
carcinogenesis in a mouse model (Azarova et al., 2007). The
MPO-dependent enhancement of the TOP2 poisoning activity
of etoposide is likely to be due to production of etoposide
phenoxy radicals and etoposide ortho-quinone in MPO-
expressing cells (see Supplemental Fig. 2A). Etoposide phe-
noxy radicals have been observed in vitro and in cell culture
systems (Haim et al., 1986; Kalyanaraman et al., 1989;
Yalowich et al., 1996; Kagan et al., 2001; Vlasova et al.,
2011) and can be further oxidized to etoposide quinone (Haim
et al., 1986; Fan et al., 2006), which exhibits enhanced TOP2-
dependent DNA cleavage activity compared with etoposide,
especially for TOP2B (Jacob et al., 2011; Smith et al., 2014b).
Etoposide ortho-quinone reacts spontaneously with GSH in
solution (Fan et al., 2006), and so the effect of MPO expression
on TOP2-DNA complex accumulation may be limited by GSH
titration of etoposide quinone within cells. Indeed, we found
that when GSH was depleted by BSO, treatment of NB4 cells
with 10 mM etoposide resulted in significantly elevated
TOP2A- and TOP2B-DNA complex accumulation (1.9- and
3.4-fold, respectively), and this effect was abolished by SA
pretreatment (Fig. 5). Notably, although glutathione deple-
tion amplified the effect of SA on etoposide induced TOP2-
DNA complexes, we were still able to measure suppression
of etoposide-induced TOP2A and TOP2B complexes in the
absence of BSO.
Although these data were mostly obtained with NB4 cells,
which express MPO at a high level (Supplemental Fig. 1) (Hu
et al., 1993), enhanced etoposide-induced TOP2-DNA complex
formation and H2AX phosphorylation were also observed in
K562 cells exogenously expressing MPO activity at less than
50% of the level of NB4 cells. For the analogous mitoxantrone
experiments, exogenously expressed MPO resulted in a 1.6-
and 2.9-fold increase in TOP2A- and TOP2B-DNA complexes,
respectively, even though MPO was only expressed at 20% of
the NB4 level. Thus, it appears that MPO can stimulate
TOP2-mediated DNA damage even when expressed at mod-
erate levels more similar to those that exist in bone marrow
myeloid precursor cells.
While our results with etoposide in NB4 cells can be
explained by etoposide redox activity in MPO expressing cells
and the finding that etoposide quinone is a more effective
TOP2 poison than its parent compound in vitro (Jacob et al.,
2011; Smith et al., 2014b), the situation is less clear for
mitoxantrone. Mitoxantrone can be oxidized by MPO, and
products of this oxidation react covalently with DNA, both in
cell-free systems and in cells (Panousis et al., 1995, 1997).
Furthermore,mitoxantrone is activated by formaldehyde, also
resulting in covalent interaction with DNA (Parker et al.,
1999). However, it is currently unclear whether the metabolic
products of mitoxantrone function as TOP2 poisons, and if so
what their relative activity is compared with the parent
compound. We show here that MPO downregulation signifi-
cantly impairs mitoxantrone-induced TOP2-DNA complex
accumulation in NB4 cells. Again the effect is larger for
TOP2B than TOP2A. For 0.5 mM mitoxantrone, SA preincu-
bation decreased TOP2B-DNA complexes to a level that was
no longer significantly above the background level obtained in
the absence of mitoxantrone. Exogenous expression of MPO in
K562 cells resulted in a more than doubling in TOP2A- and
Fig. 6. Glutathione depletion potentiates mitoxantrone-mediated TOP2
covalent complex formation and H2AX phosphorylation. NB4 cells were
preincubated with SA, BSO, or both as described for Fig 4, followed by
addition of 1 mM mitoxantrone for 1 hour. TOP2A TARDIS (A), TOP2B
TARDIS (B), and gH2AX assays (C) were performed as described in Figs 1
and 3. *P , 0.05; **P , 0.01; ***P , 0.001.
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TOP2B-DNA complexes induced by mitoxantrone. Together,
these data strongly suggest that oxidative metabolism of
mitoxantrone leads to increased TOP2A and TOP2B poison-
ing. However, our data do not distinguish between direct
enhanced poisoning of TOP2 by mitoxantrone metabolites,
and generation of DNA adducts or repair intermediates that
act as TOP2 poisons (Kingma et al., 1995; Sabourin and
Osheroff, 2000).
As was observed for etoposide, GSH depletion increased the
level of TOP2A- and TOP2B-DNA complexes induced by
mitoxantrone consistent with the involvement of a metabolite
that reacts readily with free thiols. Furthermore, high in-
tensity chemotherapy leads to depletion of thiols including
GSH (Jonas et al., 2000; Kasapovic et al., 2010; Kadam and
Abhang, 2013), and so the high level of TOP2 poison-induced
DNA damage observed in BSO-treated cells is likely to reflect
the generation of genetic lesions in bone marrow cells during
cytotoxic chemotherapy regimens.
MPO has become a target of interest for novel anti-
inflammatory drug development (Malle et al., 2007), and a
number of potent specific MPO inhibitors were recently
reported (Tidén et al., 2011; Forbes et al., 2013; Soubhye
et al., 2013, 2016; Li et al., 2015; Zheng et al., 2015). We have
used two such inhibitors, PF1355 andMPOi-II, and show that
like SA, they reduce etoposide- and mitoxantrone-induced
damage in MPO-expressing cells. Thus, novel compounds
developed for a different clinical need could, in principle, be
repurposed to reduce unwanted and carcinogenic TOP2
poison-induced genotoxic damage in critical bone marrow
cells and could have a significant impact in the frequency of
therapy-induced secondary leukemias.
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